Here's how NATURE.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NATURE . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Nature.com Make Money
  6. How Much Does Nature.com Make
  7. Keywords
  8. Topics
  9. Schema
  10. Social Networks
  11. External Links
  12. Analytics And Tracking
  13. Libraries
  14. Hosting Providers
  15. CDN Services

We are analyzing https://www.nature.com/articles/6605972.

Title:
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab | British Journal of Cancer
Description:
Phase III trials of the anti-insulin-like growth factor type 1 receptor (IGF-IR) antibody figitumumab (F) in unselected non-small-cell lung cancer (NSCLC) patients were recently discontinued owing to futility. Here, we investigated a role of free IGF-1 (fIGF-1) as a potential predictive biomarker of clinical benefit from F treatment. Pre-treatment circulating levels of fIGF-1 were tested in 110 advanced NSCLC patients enrolled in a phase II study of paclitaxel and carboplatin given alone (PC) or in combination with F at doses of 10 or 20 mg kg−1 (PCF10, PCF20). Cox proportional hazards model interactions were between 2.5 and 3.5 for fIGF-1 criteria in the 0.5–0.9 ng ml−1 range. Patients above each criterion had a substantial improvement in progression-free survival on PCF20 related to PC alone. Free IGF-1 correlated inversely with IGF binding protein 1 (IGFBP-1, ρ=−0.295, P=0.005), and the pre-treatment ratio of insulin to IGFBP-1 was also predictive of F clinical benefit. In addition, fIGF-1 levels correlated with tumour vimentin expression (ρ=0.594, P=0.021) and inversely with E-cadherin (ρ=–0.389, P=0.152), suggesting a role for fIGF-1 in tumour de-differentiation. Free IGF-1 may contribute to the identification of a subset of NSCLC patients who benefit from F therapy.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

  • Education
  • Science
  • Health & Fitness

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌆 Monumental Traffic: 20M - 50M visitors per month


Based on our best estimate, this website will receive around 41,362,249 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}


Display Ads {🎯}

$521,200 per month
According to our algorithms, Nature.com's monthly online income from display advertising ranges from $347,485 to $955,583.

Keywords {🔍}

patients, igf, figf, levels, cancer, article, growth, pcf, igfbp, google, scholar, insulin, nsclc, benefit, factor, cas, clinical, pfs, insulinlike, ratio, therapy, baseline, pretreatment, tumour, clin, nature, free, predictive, study, figure, gualberto, months, pollak, receptor, lung, bioactivity, data, igfir, binding, high, usa, circulating, treatment, criteria, analysis, identify, figitumumab, ecadherin, total, receiving,

Topics {✒️}

nature portfolio privacy policy research nature middle line represents advertising thermo scientific body mass index social media author information authors 0/ reprints italy assessing her2/neu amplification assessing k-ras mutations drug development full size image author correspondence eml4-alk gene fusion eml4-alk fusion gene open-label open label rabbit anti-pan-cytokeratin small-cell lung cancer pre-treatment circulating levels receiver-operating characteristic total alanine-scanning mutagenesis growth factor-binding proteins kaplan–meier curves plasma concentration–time curve low e-cadherin expression anti-igf-ir therapy high pre-treatment levels f-ihc aqua scores pre-treatment biomarker tests pre-treatment figf-1 levels binding protein-3-selective insulin chemotherapy-naïve stage iiib mouse anti-e-cadherin long-term clinical benefit tumour e-cadherin/vimentin ratio patients received pc significant biomarker/treatment interaction pre-treatment figf-1 criteria permissions small sample size egf receptor family progression-free survival clinical development dolled-filhart mp higher baseline levels

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
         description:Phase III trials of the anti-insulin-like growth factor type 1 receptor (IGF-IR) antibody figitumumab (F) in unselected non-small-cell lung cancer (NSCLC) patients were recently discontinued owing to futility. Here, we investigated a role of free IGF-1 (fIGF-1) as a potential predictive biomarker of clinical benefit from F treatment. Pre-treatment circulating levels of fIGF-1 were tested in 110 advanced NSCLC patients enrolled in a phase II study of paclitaxel and carboplatin given alone (PC) or in combination with F at doses of 10 or 20 mg kg−1 (PCF10, PCF20). Cox proportional hazards model interactions were between 2.5 and 3.5 for fIGF-1 criteria in the 0.5–0.9 ng ml−1 range. Patients above each criterion had a substantial improvement in progression-free survival on PCF20 related to PC alone. Free IGF-1 correlated inversely with IGF binding protein 1 (IGFBP-1, ρ=−0.295, P=0.005), and the pre-treatment ratio of insulin to IGFBP-1 was also predictive of F clinical benefit. In addition, fIGF-1 levels correlated with tumour vimentin expression (ρ=0.594, P=0.021) and inversely with E-cadherin (ρ=–0.389, P=0.152), suggesting a role for fIGF-1 in tumour de-differentiation. Free IGF-1 may contribute to the identification of a subset of NSCLC patients who benefit from F therapy.
         datePublished:2010-11-23T00:00:00Z
         dateModified:2012-03-29T00:00:00Z
         pageStart:68
         pageEnd:74
         sameAs:https://doi.org/10.1038/sj.bjc.6605972
         keywords:
            Drug therapy
            Non-small-cell lung cancer
            Predictive markers
            IGF-IR
            IGF-1
            figitumumab
            NSCLC
            Biomedicine
            general
            Cancer Research
            Epidemiology
            Molecular Medicine
            Oncology
            Drug Resistance
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6605972/MediaObjects/41416_2011_Article_BF6605972_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6605972/MediaObjects/41416_2011_Article_BF6605972_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6605972/MediaObjects/41416_2011_Article_BF6605972_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6605972/MediaObjects/41416_2011_Article_BF6605972_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6605972/MediaObjects/41416_2011_Article_BF6605972_Fig5_HTML.jpg
         isPartOf:
            name:British Journal of Cancer
            issn:
               1532-1827
               0007-0920
            volumeNumber:104
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:A Gualberto
               affiliation:
                     name:Pfizer Oncology
                     address:
                        name:The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, USA
                        type:PostalAddress
                     type:Organization
                     name:Warren Alpert Medical School at Brown University
                     address:
                        name:Department of Pathology and Laboratory Medicine, Warren Alpert Medical School at Brown University, Providence, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:M L Hixon
               affiliation:
                     name:Warren Alpert Medical School at Brown University
                     address:
                        name:Department of Pathology and Laboratory Medicine, Warren Alpert Medical School at Brown University, Providence, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:D D Karp
               affiliation:
                     name:MD Anderson Cancer Center
                     address:
                        name:Department of Thoracic Oncology, MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:D Li
               affiliation:
                     name:Pfizer Oncology
                     address:
                        name:The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S Green
               affiliation:
                     name:Pfizer Oncology
                     address:
                        name:The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M Dolled-Filhart
               affiliation:
                     name:HistoRx Inc.
                     address:
                        name:HistoRx Inc., New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:L G Paz-Ares
               affiliation:
                     name:Virgen del Rocio University Hospital
                     address:
                        name:Department of Medical Oncology, Virgen del Rocio University Hospital, Seville, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S Novello
               affiliation:
                     name:University of Turin, Orbassano
                     address:
                        name:Department of Medical Oncology, University of Turin, Orbassano, Turin, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J Blakely
               affiliation:
                     name:West Clinic
                     address:
                        name:Department of Medical Oncology, West Clinic, Memphis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:C J Langer
               affiliation:
                     name:Abramson Cancer Center, University of Pennsylvania
                     address:
                        name:Hematology/Oncology Division, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M N Pollak
               affiliation:
                     name:McGill University
                     address:
                        name:Department of Medical Oncology, McGill University, Montreal, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
      description:Phase III trials of the anti-insulin-like growth factor type 1 receptor (IGF-IR) antibody figitumumab (F) in unselected non-small-cell lung cancer (NSCLC) patients were recently discontinued owing to futility. Here, we investigated a role of free IGF-1 (fIGF-1) as a potential predictive biomarker of clinical benefit from F treatment. Pre-treatment circulating levels of fIGF-1 were tested in 110 advanced NSCLC patients enrolled in a phase II study of paclitaxel and carboplatin given alone (PC) or in combination with F at doses of 10 or 20 mg kg−1 (PCF10, PCF20). Cox proportional hazards model interactions were between 2.5 and 3.5 for fIGF-1 criteria in the 0.5–0.9 ng ml−1 range. Patients above each criterion had a substantial improvement in progression-free survival on PCF20 related to PC alone. Free IGF-1 correlated inversely with IGF binding protein 1 (IGFBP-1, ρ=−0.295, P=0.005), and the pre-treatment ratio of insulin to IGFBP-1 was also predictive of F clinical benefit. In addition, fIGF-1 levels correlated with tumour vimentin expression (ρ=0.594, P=0.021) and inversely with E-cadherin (ρ=–0.389, P=0.152), suggesting a role for fIGF-1 in tumour de-differentiation. Free IGF-1 may contribute to the identification of a subset of NSCLC patients who benefit from F therapy.
      datePublished:2010-11-23T00:00:00Z
      dateModified:2012-03-29T00:00:00Z
      pageStart:68
      pageEnd:74
      sameAs:https://doi.org/10.1038/sj.bjc.6605972
      keywords:
         Drug therapy
         Non-small-cell lung cancer
         Predictive markers
         IGF-IR
         IGF-1
         figitumumab
         NSCLC
         Biomedicine
         general
         Cancer Research
         Epidemiology
         Molecular Medicine
         Oncology
         Drug Resistance
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6605972/MediaObjects/41416_2011_Article_BF6605972_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6605972/MediaObjects/41416_2011_Article_BF6605972_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6605972/MediaObjects/41416_2011_Article_BF6605972_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6605972/MediaObjects/41416_2011_Article_BF6605972_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6605972/MediaObjects/41416_2011_Article_BF6605972_Fig5_HTML.jpg
      isPartOf:
         name:British Journal of Cancer
         issn:
            1532-1827
            0007-0920
         volumeNumber:104
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:A Gualberto
            affiliation:
                  name:Pfizer Oncology
                  address:
                     name:The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, USA
                     type:PostalAddress
                  type:Organization
                  name:Warren Alpert Medical School at Brown University
                  address:
                     name:Department of Pathology and Laboratory Medicine, Warren Alpert Medical School at Brown University, Providence, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:M L Hixon
            affiliation:
                  name:Warren Alpert Medical School at Brown University
                  address:
                     name:Department of Pathology and Laboratory Medicine, Warren Alpert Medical School at Brown University, Providence, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D D Karp
            affiliation:
                  name:MD Anderson Cancer Center
                  address:
                     name:Department of Thoracic Oncology, MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D Li
            affiliation:
                  name:Pfizer Oncology
                  address:
                     name:The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S Green
            affiliation:
                  name:Pfizer Oncology
                  address:
                     name:The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M Dolled-Filhart
            affiliation:
                  name:HistoRx Inc.
                  address:
                     name:HistoRx Inc., New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:L G Paz-Ares
            affiliation:
                  name:Virgen del Rocio University Hospital
                  address:
                     name:Department of Medical Oncology, Virgen del Rocio University Hospital, Seville, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S Novello
            affiliation:
                  name:University of Turin, Orbassano
                  address:
                     name:Department of Medical Oncology, University of Turin, Orbassano, Turin, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J Blakely
            affiliation:
                  name:West Clinic
                  address:
                     name:Department of Medical Oncology, West Clinic, Memphis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:C J Langer
            affiliation:
                  name:Abramson Cancer Center, University of Pennsylvania
                  address:
                     name:Hematology/Oncology Division, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M N Pollak
            affiliation:
                  name:McGill University
                  address:
                     name:Department of Medical Oncology, McGill University, Montreal, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:British Journal of Cancer
      issn:
         1532-1827
         0007-0920
      volumeNumber:104
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Pfizer Oncology
      address:
         name:The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, USA
         type:PostalAddress
      name:Warren Alpert Medical School at Brown University
      address:
         name:Department of Pathology and Laboratory Medicine, Warren Alpert Medical School at Brown University, Providence, USA
         type:PostalAddress
      name:Warren Alpert Medical School at Brown University
      address:
         name:Department of Pathology and Laboratory Medicine, Warren Alpert Medical School at Brown University, Providence, USA
         type:PostalAddress
      name:MD Anderson Cancer Center
      address:
         name:Department of Thoracic Oncology, MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:Pfizer Oncology
      address:
         name:The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, USA
         type:PostalAddress
      name:Pfizer Oncology
      address:
         name:The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, USA
         type:PostalAddress
      name:HistoRx Inc.
      address:
         name:HistoRx Inc., New Haven, USA
         type:PostalAddress
      name:Virgen del Rocio University Hospital
      address:
         name:Department of Medical Oncology, Virgen del Rocio University Hospital, Seville, Spain
         type:PostalAddress
      name:University of Turin, Orbassano
      address:
         name:Department of Medical Oncology, University of Turin, Orbassano, Turin, Italy
         type:PostalAddress
      name:West Clinic
      address:
         name:Department of Medical Oncology, West Clinic, Memphis, USA
         type:PostalAddress
      name:Abramson Cancer Center, University of Pennsylvania
      address:
         name:Hematology/Oncology Division, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
         type:PostalAddress
      name:McGill University
      address:
         name:Department of Medical Oncology, McGill University, Montreal, Canada
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:A Gualberto
      affiliation:
            name:Pfizer Oncology
            address:
               name:The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, USA
               type:PostalAddress
            type:Organization
            name:Warren Alpert Medical School at Brown University
            address:
               name:Department of Pathology and Laboratory Medicine, Warren Alpert Medical School at Brown University, Providence, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:M L Hixon
      affiliation:
            name:Warren Alpert Medical School at Brown University
            address:
               name:Department of Pathology and Laboratory Medicine, Warren Alpert Medical School at Brown University, Providence, USA
               type:PostalAddress
            type:Organization
      name:D D Karp
      affiliation:
            name:MD Anderson Cancer Center
            address:
               name:Department of Thoracic Oncology, MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      name:D Li
      affiliation:
            name:Pfizer Oncology
            address:
               name:The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, USA
               type:PostalAddress
            type:Organization
      name:S Green
      affiliation:
            name:Pfizer Oncology
            address:
               name:The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, USA
               type:PostalAddress
            type:Organization
      name:M Dolled-Filhart
      affiliation:
            name:HistoRx Inc.
            address:
               name:HistoRx Inc., New Haven, USA
               type:PostalAddress
            type:Organization
      name:L G Paz-Ares
      affiliation:
            name:Virgen del Rocio University Hospital
            address:
               name:Department of Medical Oncology, Virgen del Rocio University Hospital, Seville, Spain
               type:PostalAddress
            type:Organization
      name:S Novello
      affiliation:
            name:University of Turin, Orbassano
            address:
               name:Department of Medical Oncology, University of Turin, Orbassano, Turin, Italy
               type:PostalAddress
            type:Organization
      name:J Blakely
      affiliation:
            name:West Clinic
            address:
               name:Department of Medical Oncology, West Clinic, Memphis, USA
               type:PostalAddress
            type:Organization
      name:C J Langer
      affiliation:
            name:Abramson Cancer Center, University of Pennsylvania
            address:
               name:Hematology/Oncology Division, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:M N Pollak
      affiliation:
            name:McGill University
            address:
               name:Department of Medical Oncology, McGill University, Montreal, Canada
               type:PostalAddress
            type:Organization
PostalAddress:
      name:The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, USA
      name:Department of Pathology and Laboratory Medicine, Warren Alpert Medical School at Brown University, Providence, USA
      name:Department of Pathology and Laboratory Medicine, Warren Alpert Medical School at Brown University, Providence, USA
      name:Department of Thoracic Oncology, MD Anderson Cancer Center, Houston, USA
      name:The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, USA
      name:The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, USA
      name:HistoRx Inc., New Haven, USA
      name:Department of Medical Oncology, Virgen del Rocio University Hospital, Seville, Spain
      name:Department of Medical Oncology, University of Turin, Orbassano, Turin, Italy
      name:Department of Medical Oncology, West Clinic, Memphis, USA
      name:Hematology/Oncology Division, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
      name:Department of Medical Oncology, McGill University, Montreal, Canada

Social Networks {👍}(1)

External Links {🔗}(103)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mxa-002c5801.gslb.pphosted.com
  • mxb-002c5801.gslb.pphosted.com

Name Servers:

  • pdns1.ultradns.net
  • pdns2.ultradns.net
  • pdns3.ultradns.org
  • pdns4.ultradns.org
  • pdns5.ultradns.info
  • pdns6.ultradns.co.uk

CDN Services {📦}

  • Crossref

4.42s.